This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Edward V. Henry, MD
Clinical Drug Safety Department Geigy Pharmaceuticals Summit, NJ 07901

Arch Neurol. 1980;37(5):326.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Reference is made to the report by Dr Berchou (ARCHIVES 36:522-523, 1979) concerning a case of oculogyric crisis occurring in association with carbamazepine (Tegretol) therapy. In our discussion with Dr Berchou prior to his published report, we noted that oculomotor disturbances are listed in our package insert for carbamazepine as possible adverse reactions. The clinical findings described by Dr Berchou would be included under that classification. Those oculomotor disturbances that have been reported seem to be related to dosage, and usually are controlled by titration of carbamazepine to the minimum effective dose level. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?